In early, androgen dependent stages of prostate cancer, androgen withdrawal, the major course of therapy in prostate cancer, leads to a rapid regression of the tumor as a result of apoptosis. However, prostate cancer invariably progresses to an androgen independent and apoptosis resistant stage for which no curative treatment is available. The molecular details of regression upon androgen withdrawal and progression to a resistant state are largely unknown. Here we show that c-Jun Nterminal Kinase (JNK) is activated strongly and in a sustained fashion by 12-O-tetradecanoylphorbol 13-acetate (TPA) and thapsigargin (TG), two agents which were previously shown to lead to apoptosis in the androgen responsive prostate cancer cell line LNCaP. The time course of JNK induction by both compounds correlated very well with the onset and progression of apoptosis in LNCaP cells. Inhibition of either ERK or p38 pathways did not aect TPA-induced cell death. In the androgenindependent prostate cancer cell lines DU-145 and PC-3, and in the cervical carcinoma cell line HeLaS3, TPA did not lead to apoptosis and there were no signi®cant changes in JNK activity upon TPA treatment. The failure of TPA to induce JNK activity in PC-3, DU-145, and HelaS3 cells was not due to a general defect in JNK signaling since ultraviolet (UV) irradiation dramatically increased JNK activity in all four cell lines. Speci®c inhibition of JNK by expression of the JNK Inhibitory Protein (JIP) dramatically inhibited both TPA-and TGinduced apoptosis. Furthermore, apoptosis induced by both agents was completely blocked by ectopic expression of the baculovirus caspase-inhibitor P35. Surprisingly, ZVAD-fmk, a cell-permeable¯uoromethylketone inhibitor of caspases, had no eect on TPA-induced apoptosis, whereas it completely inhibited TG-induced cell death; JNK activity was not aected in either case. This indicates that ZVAD-fmk does not inhibit some of the caspases involved in TPA-induced apoptosis, and that despite the common requirement of JNK activation, TPAand TG-induced cell death are mechanistically dierent. Furthermore, it also suggests that JNK is either upstream or independent of caspases in LNCaP cells. Collectively, these results indicate that apoptosis in LNCaP cells requires a sustained increase in JNK activity and caspase activation; components of these signaling pathways may be defective in the androgen independent prostate cancer cell lines.
Introduction
Apoptosis is a highly regulated form of cell death that eliminates unwanted cells from the body (Kerr et al., 1972 , for recent reviews, see Chinnaiyan and Dixit, 1996; Ellis et al., 1991; Jacobson et al., 1997; White, 1996) . Cells that are undergoing apoptosis typically display a characteristic set of morphological changes, such as condensation of the cytoplasm and the nucleus, plasma membrane blebbing, nuclear fragmentation, and ®nally the fragmentation of the cell into apoptotic bodies that are rapidly phagocytosed (Kerr et al., 1972) .
An intracellular signaling pathway that has recently been implicated in the regulation of apoptosis is the mitogen-activated protein kinase (MAPK) cascade (for reviews, see Minden and Karin, 1997; Lewis et al., 1998; Widmann et al., 1999) . MAPKs are serine/ threonine kinases that are activated by diverse stimuli, such as cytokines, growth factors, neurotransmitters, hormones, cellular stress and interactions with the extracellular matrix. The substrates of MAPKs that have been recognized thus far are equally varied and include transcription factors, metabolic enzymes, cytoskeletal proteins and other signaling molecules. As would be expected from this broad substrate target, MAPKs have been shown to be involved in such diverse cellular processes as cell growth, meiosis, dierentiation, and most recently also apoptosis.
MAPK cascades are comprised of a three-tiered kinase module and are found in all eukaryotic organisms. This includes a MAPK, which is activated by a MAPK kinase (MAPKK), which in turn is activated by a MAPKK kinase (MAPKKK) (for a review see Widmann et al., 1999) . The three major and best studied MAPK pathways are those which result in the activation of: (i) extracellular signal regulated kinases (ERKs); (ii) c-Jun NH 2 -terminal kinase/stressactivated protein kinases (JNKs/SAPKs) and (iii) p38 MAPKs.
The involvement of MAPK pathways in apoptosis has recently been recognized. Early studies correlated JNK and p38 with apoptosis whereas ERK was implicated in proliferation and protection from apoptosis (e.g. Xia et al., 1995) . However, it later became clear that it is dicult to generalize about the speci®c roles of MAPKs on apoptosis since these appear to depend on the apoptotic signal, the cell type, and the conditions being used (for reviews, see Karin, 1998; Lewis et al., 1998; Robinson and Cobb, 1997) . For example, in PC12 cells withdrawal of nerve growth factor causes apoptosis and activates JNK/SAPK and p38, and at the same time inhibits ERKs (Xia et al., 1995) . Conversely, activation of JNK/SAPK is not sucient to induce apoptosis mediated by tumor necrosis factor in MCF7 or L929 cells (Liu et al., 1996) , and blocking of JNK activity has no eect on Fas-mediated apoptosis in Jurkat cells (Lenczowski et al., 1997) .
Both the prostate gland and prostate cancer in its initial stages are dependent on androgens for growth and maintenance (for a review, see Isaacs, 1994) . Consequently, removal of androgens induces rapid involution, mainly due to an increase in apoptosis Stattin et al., 1998) . This is the basis for hormone ablation therapy in prostate cancer when the tumor is still hormone-dependent (Huggins and Hodges, 1941; Moore, 1994) .
As a model for androgen ablation-induced apoptosis in prostate cancer, the androgen responsive (but not dependent) prostate cancer cell line LNCaP (Horoszewicz et al., 1983) has previously been used. Apoptosis can be induced in LNCaP cells by the phorbol ester 12-O-tetradecanoyl-13-phorbol-acetate (TPA), which activates PKC (Day et al., 1994; Young et al., 1994; Garzotto et al., 1998) or thapsigargin (TG), an inhibitor of Ca 2+ -ATPase present in the endoplasmatic reticulum (McConkey et al., 1996) . Even though it is well documented in LNCaP cells that these two agents induce morphological changes associated with apoptosis, such as chromatin condensation and nuclear fragmentation, details of the molecular events that mediate the cell death program are largely unknown.
In this study, we have assessed possible changes in MAPK activity during apoptosis of LNCaP cells compared with apoptosis-resistant, androgen-independent prostate cancer cell lines, and a non-prostate cancer cell line as control. We found excellent correlation between activation of JNK and the onset of apoptosis induced in LNCaP cells by both TPA and TG. In contrast, there was no signi®cant change in JNK activity in the apoptosis resistant prostate cancer cell lines PC-3 and DU-145 in response to TPA. Speci®c inhibition of JNK by expression of JNK Inhibitory Protein (JIP) signi®cantly reduced both TPA-and TG-induced apoptosis in LNCaP cells, indicating that JNK activation is required for apoptosis in these cells. Expression of P35, a baculovirus caspase-inhibitor, blocked both TPA-and TG-induced apoptosis, whereas the synthetic caspase inhibitor ZVAD-fmk inhibited TG-induced cell death, but did not aect TPA-induced apoptosis. Furthermore, TPA-or TG-induced JNK activity was not aected by ZVAD-fmk. These results indicate that JNK and caspases are directly involved in apoptosis of androgen sensitive prostate cancer cells; components of the signaling pathways involving JNK may be defective in the androgen independent cell lines.
Results

JNK activity is increased during TPA-induced apoptosis in LNCaP cells
As a model system to study apoptosis in prostate cancer cells, we used the phorbol ester 12-O-tetradecanoyl-13-phorbol-acetate (TPA), which was previously reported to induce apoptosis in the androgen responsive prostate cancer cell line LNCaP (Day et al., 1994; Young et al., 1994; Garzotto et al., 1998) . In agreement with these earlier studies, TPA treatment of LNCaP cells for 24 h resulted in typical morphological changes characteristic of apoptosis, such as cell shrinkage and membrane blebbing, condensation and fragmentation of nuclei, and internucleosomal fragmentation of DNA (data not shown). Under the same conditions, there was no indication of apoptosis in the androgen independent prostate cancer cell lines DU-145 and PC-3, or in the non-prostatic tumor cell line HeLaS3, consistent with previous ®ndings (Young et al., 1994; Henttu and Vihko, 1998; Kinzel et al., 1988) (data not shown).
We next established the time-course of the onset of apoptotic cell death upon TPA treatment under our experimental conditions using the trypan blue assay. As shown in Figure 1a , LNCaP cell death started at about 6 h after TPA addition and then increased sharply with time, reaching maximal levels at about 24 h, when approximately 25% of the cells were apoptotic. Similar results were obtained by Hoechst 33258 staining and visualization of cells that exhibit condensed or fragmented nuclei characteristic of apoptosis (data not shown).
During apoptosis, activation of caspases results in cleavage of the DNA repair enzyme poly(ADP)-ribosepolymerase (PARP), one of the target proteins for caspases (Gu et al., 1995; Nicholson et al., 1995) . Thus, proteolytic cleavage of the 113 kD PARP into 89 kD and 24 kD fragments, is a sign of caspase activation and apoptosis. To assess if caspases are activated during TPA-induced apoptosis in LNCaP cells, whole cell extracts from TPA-treated LNCaP cells were used in Western analysis with a PARP-speci®c antiserum.
TPA treatment led to a gradual decrease in the levels of full length PARP protein which was ®rst detectable after 12 h of TPA treatment and was further decreased at 24 and 48 h (data not shown). As shown in Figure  1b , the 89 kD proteolytic PARP fragment ®rst appeared after 12 h, and increased in strength at 24 h. This indicates that TPA-induced apoptosis in LNCaP cells is accompanied by caspase activation.
Previous studies have implicated MAPK cascades in mediating apoptosis in several cell types (for reviews, see Lewis et al., 1998; Minden and Karin, 1997; Robinson and Cobb, 1997; Widmann et al., 1999) . We therefore examined potential changes in MAPK activity in LNCaP cells that are going through apoptosis in response to TPA. We ®rst investigated possible alterations in JNK activity by using the solid phase kinase assay with GST-cJun (1 ± 93) as substrate (Hibi et al., 1993) . As shown in Figure 1c , there was a signi®cant, biphasic increase in JNK activity in response to TPA treatment. Half an hour after TPA addition, JNK activity was increased about threefold, but it was reduced back down to basal level within 6 h. The second activation started between 6 and 12 h, the same time period during which the start of signi®cant apoptosis could be discerned (Figure 1a,b) , and was sustained for at least 12 ± 18 h. After 24 h, JNK activity dropped, and was reduced to basal levels by 48 h. These results were con®rmed by Western analysis using antibodies that speci®cally recognize the active, phosphorylated form of JNK (data not shown). Western analysis using an antiserum that recognizes JNK independently of its phosphorylation state, showed that the increase in JNK activity was not due to an increase in total JNK protein levels (data not shown). Thus, the initiation of apoptosis by TPA in LNCaP cells is very well correlated with a sustained increase in JNK activity.
As noted above, TPA does not lead to apoptosis in the androgen-independent prostate cancer cell lines DU-145 and PC-3, or in the cervical carcinoma cell line HeLa. Thus, if the sustained activation of JNK is involved in the apoptotic process, TPA should not cause a sustained increase in JNK activity in these cell lines under our experimental conditions. We therefore treated these dierent cell lines with TPA under the same conditions as LNCaP cells and assessed changes in JNK activity using the solid phase kinase assay as described in Figure 1c . As shown in Figure 2a , basal levels of JNK activity were somewhat dierent among the dierent cell lines, being highest in DU-145 and lowest in PC-3 cells. Whereas TPA treatment eciently increased JNK activity in LNCaP cells, there was no signi®cant increase in JNK activity in the other cell lines.
To assess if the lack of JNK activation in response to TPA was due to a general defect in the JNK signaling cascade in these cell lines, another inducer of JNK, ultraviolet (UV) irradiation, was used (Hibi et al., 1993; Derijard et al., 1994) . LNCaP, PC-3, DU-145, and HeLa cells were exposed to UV irradiation, whole cell extracts were prepared and used in the solid phase kinase assay. As shown in Figure 2b , exposure to UV resulted in 10 ± 20-fold increase in JNK activity in all cell lines tested. Therefore, the lack of inducibility of JNK was not due to a defect in JNK in these cell lines.
We next assessed if ERK and p38, the two other major MAPKs in the cell, may be involved in TPAinduced apoptosis in LNCaP cells. Speci®c, cell permeable compounds PD98059 and SB203580, which inhibit ERK or p38 pathways, respectively, did not alter TPA-induced apoptosis in LNCaP cells (data not shown). In addition, Western analysis of phosphorylated, and therefore activated ERK, did not correlate with the time course of apoptosis induced by TPA (data not shown). These data suggest that JNK is the Whole cell extracts were prepared and used in Western blot analysis with an anti-PARP antiserum as described in Materials and methods. (c) LNCaP cells were maintained and treated with TPA as described in b. Cells were harvested at dierent time points, whole cell extracts were prepared, and approximately 50 mg of total protein was used in the solid phase kinase assay as described in Materials and methods. A representative experiment repeated at least three times is shown. The quanti®cation of the bands by phosphoimager analysis from at least three independent experiments (that did not deviate by more than 20%) is presented below each band major MAPK that is involved in mediating apoptosis of LNCaP cells.
JNK activity is increased during thapsigargin-induced apoptosis in LNCaP cells
Thapsigargin (TG) is a speci®c inhibitor of Ca 2+ -ATPase present in the endoplasmatic reticulum (for a review, see Treiman et al., 1998) and was previously shown to induce apoptosis in LNCaP cells (McConkey et al., 1996) . TG has also been reported to induce JNK activity in several non-prostate cell lines (Araki et al., 1997; Li et al., 1997; Nagahara et al., 1998; Srivastava et al., 1999; Urano et al., 2000) whereas it has no eect on JNK activity in some other cell types (Kuroki et al., 1996; Shrode et al., 1997) . Thus, activation of JNK by TG may be cell-type speci®c. We therefore assessed whether TG treatment resulted in any changes in JNK activity in LNCaP cells.
We ®rst determined the concentration of TG that induces apoptosis in LNCaP cells. While 10 nM TG had little eect on cell viability, treatment with 100 nM and 1 mM resulted in about 50% cell death after 48 h, as measured by the Trypan blue exclusion assay (data not shown). A concentration of 100 nM was therefore chosen for the following studies. Treatment of LNCaP cells with 100 nM TG for 48 h resulted in typical signs of apoptosis, such as cell shrinkage, condensation and fragmentation of nuclei, and internucleosomal fragmentation of DNA (data not shown). The kinetics of cell death was examined by the Trypan blue assay. As shown in Figure 3a , there was little or no change in the viability of LNCaP cells during the ®rst 24 h of TG treatment. Between 24 and 36 h, however, substantial levels of cell death started to occur, and approximately 50% of the cells were dead at 48 h.
To assess if TG-induced cell death involves activation of caspases, LNCaP cells were treated with TG for increasing amounts of time, and whole cell extracts were prepared. The extracts were then used in Western analysis with a PARP-speci®c antiserum. As shown in Figure 3b , the proteolytic cleavage of PARP was ®rst detected at 36 h, the time point at which signi®cant cell death begins (Figure 3a ), and increased with time, indicating that TG-induced apoptosis in LNCaP cells is accompanied by caspase activation.
To determine whether there were changes in JNK activity during TG-induced apoptosis in LNCaP cells, whole cell extracts prepared from TG-treated LNCaP cells were utilized in the solid phase kinase assay using GST-cJun (1 ± 93) as a substrate. As shown in Figure  3c , there was a modest (approximately twofold), early activation of JNK activity at 30 min which was lost by 6 h. A second, much stronger (up to 5.5-fold) increase in JNK activity occurred between 24 and 48 h, concurrent with apoptosis. These results were con®rmed by Western analysis using phospho-JNK speci®c antibodies (data not shown). The increase in JNK activity was not due to an increase in JNK protein levels, since Western analysis of the same extracts using an antiserum that recognizes total JNK proteins did not show any signi®cant variation (Figure 3d) . Interestingly, however, a band just below p55 reproducibly appeared at 36 h and was further increased at 48 h. This could correspond to an isoform of JNK whose expression is induced by TG, or alternatively, proteolytic cleavage of a JNK isoform. Further work is required to assess the identity of this band and its possible role in TG-induced apoptosis in LNCaP cells.
Specific inhibition of JNK or ectopic expression of P35 protects LNCaP cells from TPA-induced apoptosis
The above data, obtained with two dierent inducers of apoptosis, suggested that a sustained increase in JNK activity is necessary for the induction of apoptosis in LNCaP cells. To de®nitively test this hypothesis, we speci®cally inhibited JNK activity and determined if apoptosis still occurred. Since a cell permeable, speci®c JNK inhibitor has not been described to date, we utilized the JNK-interacting protein-1 (JIP-1), a cytoplasmic protein which binds to, and when overexpressed, speci®cally inhibits JNK activation (Dickens The various cell lines were maintained and treated with TPA as described in Materials and methods. Cells were harvested at the indicated time points and JNK activity was determined using the solid phase kinase assay as in Figure 1c . The results from at least three independent experiments quantitated by phosphorimager analysis is shown. JNK activity at 30 min of TPA induction in LNCaP cells was arbitrarily set at 100. (b) Ultraviolet light eciently induces JNK activity in all the cell lines tested. Cells were maintained and were exposed to UV light as described in Materials and methods. Whole cell extracts were then prepared and used in the solid phase kinase assay. A representative experiment that was repeated twice is shown. GSTc-Jun phosphorylation was quantitated by phosphorimager analysis and average values are presented under each lane (Relative intensities, marked Rel.Int.). Note that there appears to be very low level of basal activity here compared with that in Figure 1c ; this is due to the relatively weak JNK induction by TPA compared to UV, and consequently the exposure of the gel from the UV extracts is much shorter et al., 1997; Yasuda et al., 1999 ). An expression vector encoding the JNK binding domain (JBD) of JIP-1 (pcDNA3-Flag-JBD); (Dickens et al., 1997) was introduced into LNCaP cells by transient transfection. The cells were cotransfected with a vector encoding Green Fluorescent Protein (pEGFP-C1) for subsequent visualization of the transfected cells. As a control, cells were cotransfected with pEGFP-C1 and pUC18. After transfection, cells were treated with TPA for 24 h, i.e. when apoptosis and JNK activity are maximal (see Figure 1) . Subsequently, the nuclei of GFP-transfected cells were examined and scored for apoptotic features (nuclear condensation and fragmentation).
Representative vision ®elds from such an experiment with TPA is shown in Figure 4a . Whereas some of the cells that were transfected with the GFP expression vector together with pUC18 were apoptotic (indicated by the fragmented nuclei), cells that were transfected with JBD were signi®cantly protected from apoptosis.
To assess if caspases are involved in TPA-mediated apoptosis in LNCaP cells, the eect of the baculovirus caspase inhibitor P35 protein (Clem and Miller, 1994 ; for a review, see Miller, 1997) was tested in parallel with the experiments described above for JBD. LNCaP cells were either transfected with GFP and control vector, or GFP together with a vector specifying expression of P35 (pCI-P35) (Bertin et al., 1997) . Cell nuclei were visualized by Hoechst staining and were scored for apoptotic features. As shown in Figure 4a , P35 expression protected LNCaP cells from TPAinduced apoptosis.
The results of JBD or P35 expression on TPAinduced apoptosis in LNCaP cells obtained in the above experiments are quantitatively represented in a bar graph in Figure 4b where at least 600 cells for each experimental condition were scored. Whereas the background cell death was about 10% of total transfected cells (due to the procedure used; see Materials and methods), TPA treatment increased it to 30%. However, when JBD was ectopically expressed, the percentage of apoptotic cells in the presence of TPA was decreased to 15% a 75%-inhibition of TPA-induced apoptosis (Figure 4b) . Interestingly, in the presence of P35, the basal level of apoptosis observed with this procedure was signi®cantly decreased, from approximately 10% to 2%, indicating that it also occurs through a caspasedependent pathway, probably initiated by the transfection reagent lipofectin used in these experiments. Furthermore, TPA-induced apoptosis was completely blocked by P35 expression.
Specific inhibition of JNK or ectopic expression of P35 protects LNCaP cells from TG-induced apoptosis
We then investigated whether JBD and P35 similarly aect TG-induced apoptosis in LNCaP cells. As described above, cells were cotransfected with pEGFP-C1 and either pUC18 as control, or expression vectors specifying JBD or P35. After transfection, cells were treated with TG for 42 h and the nuclei of GFPtransfected cells were examined for nuclear condensation and fragmentation. As shown in Figure 5a , both JBD and P35 expression protected LNCaP cells from apoptosis. This is represented quantitatively in a bar graph in Figure 5b . The percentage of apoptotic cells was increased from approximately 3% in control cells Whole cell extracts were prepared and used in Western analysis with a PARP antiserum as described in Materials and methods. (c) LNCaP cells were treated with TG (100 nM) for the indicated times, whole cell extracts were prepared and used in the solid phase kinase assay with GST-cJun as substrate. The results of an experiment that was repeated twice are shown. The bands were quantitated by phosphorimager analysis, and the average intensities (relative values, marked Rel.Int.) from two independent experiments with essentially identical results are presented at the bottom of the ®gure. (d) TG treatment does not aect JNK protein levels in LNCaP cells. The same extracts as in c were used in Western analysis with an antiserum that recognizes the total JNK protein in the cell as described in Materials and methods. There is one major band at 55 kD which is likely to be JNK2. The two less abundant bands at 42 and 46 kD are likely to be splice variants of JNK1. However, since there are multiple splice variants of both JNK1 and JNK2 that may have similar molecular weight, our labeling is based on the most common forms Oncogene JNK activation and apoptosis in prostate cancer cells N Engedal et al to 23% in TG-treated cells. In the presence of ectopic JBD expression, apoptotic cells were decreased to about 10% of total, or a 73% drop in TG-induced apoptosis, whereas in the presence of P35 there was a decrease of more than 90% in TG-induced apoptosis. These data provide strong evidence that JNK is directly involved in mediating both TPA-and TGinduced apoptosis in LNCaP cells.
To determine whether JBD expression in the above experiments inhibited JNK activity in LNCaP cells, we examined the transcriptional activity of c-Jun, which is dependent on JNK for transactivation (for a review, see Minden and Karin, 1997) . To that end, we examined the activity of a fusion protein consisting of the GAL4 DNA binding domain and the c-Jun transactivation domain (GAL4-cJun) in the presence or absence of JBD expression. LNCaP cells were transfected with 5XGAL4-LUC, a GAL4 responsive reporter, and GAL4-cJun, in the presence of either an empty expression vector (pcDNA3) or a vector specifying the expression of JBD (pcDNA3-Flag-JBD) (Dickens et al., 1997) . After transfection, cells were treated with TPA, harvested after 16 h, and LUC activities were determined. As shown in Figure  5c , in the absence of GAL4-cJun, there was low activation of 5XGAL4-LUC. In the presence of GAL4-cJun, 5XGAL4-LUC expression was stimulated approximately sixfold and was not signi®cantly aected in the presence of increasing amounts of the empty expression vector pcDNA3. In contrast, when increasing amounts of the JBD expression vector were transfected, there was a signi®cant, dose-dependent decrease in 5XGAL4-LUC activation back to basal levels. Very similar results were obtained when TG was used as the inducer (data not shown). These results indicate that JBD is functional and speci®cally inhibits both TPA-and TG-induced JNK activation in LNCaP cells.
ZVAD-fmk protects LNCaP cells from TG-, but not TPA-induced apoptosis
We next tested the eect of the cell-permeable, synthetic caspase-inhibitor ZVAD-fmk (Chow et al., 1995; Zhu et al., 1995) on TPA-and TG-induced apoptosis in LNCaP cells. LNCaP cells were either left untreated or treated with TG in the presence or absence of ZVAD-fmk, and cell viability was determined by the Trypan blue assay. As shown in Figure  6a , ZVAD-fmk had no eect when added to untreated cells. However, while TG treatment alone resulted in about 50% cell death after 48 h, simultaneous treatment with ZVAD-fmk completely protected LNCaP cells from TG-induced apoptosis. Phase contrast microscopy revealed that cells simultaneously treated with TG and ZVAD-fmk did not show any detectable morphological changes compared with untreated cells (data not shown). Moreover, ZVADfmk fully inhibited TG-induced PARP-cleavage at 48 h (Figure 6b ), demonstrating that caspase inhibition indeed occurred.
We also assessed the eect of ZVAD-fmk on TPAinduced apoptosis in LNCaP cells. LNCaP cells were either left untreated or treated with TPA in the presence or absence of ZVAD-fmk, and cell viability was determined. Surprisingly, the same concentration of ZVAD-fmk that completely blocked TG-induced apoptosis (50 mM) had no eect on TPA-induced apoptosis (data not shown). Addition of ZVAD-fmk up to 4 h before the addition of TPA and the use of up to fourfold higher concentration (200 mM) did not aect TPA-induced cell death. An example of these experiments is shown in Figure 6c , where 200 mM Figure 4b . (c) JBD inhibits TPA-induced JNK activity in LNCaP cells. LNCaP cells were transfected with 5XGAL4-LUC, a GAL4 responsive reporter, and GAL4-cJun (100 ng), in the presence of either an empty expression vector (pCDNA3; 100, 250, and 500 ng) or the same amounts of a vector specifying expression of JBD (pcDNA3-Flag-JBD) as indicated. After transfection, cells were treated with TPA (5 ng/ ml), harvested after 16 h, and LUC activities were determined. Results shown are from an experiment done in triplicate which was repeated at least three times with similar results. LUC activity in the presence of GAL4-cJun was arbitrarily set at 100 ZVAD-fmk was added 4 h before TPA, and cells were scored for viability 24 h after TPA addition: ZVADfmk still had no eect on TPA-induced cell death in LNCaP cells. No dierences in cellular morphology could be discerned between cells treated with TPA alone and cells that were simultaneously treated with TPA and ZVAD-fmk by phase contrast microscopy (data not shown).
We then determined if ZVAD-fmk aects the TPAinduced PARP cleavage that is associated with apoptosis ( Figure 1) . Interestingly, under the same conditions, ZVAD-fmk completely blocked TPA-induced PARP-cleavage, as shown by Western blot analysis (Figure 6d) . Thus, while caspases that mediate PARP-cleavage are inhibited, ZVAD-fmk cannot protect LNCaP cells from TPA-induced apoptosis.
TPA-and TG-induced activation of JNK is not inhibited by ZVAD-fmk
The data presented so far indicated that both TPAand TG-induced apoptosis in LNCaP cells require JNK and caspase activation. We therefore investigated the possible relationship between JNK and caspase activation in response to TPA and TG in LNCaP cells. Following treatment with TPA or TG in the presence or absence of ZVAD-fmk, whole cell extracts were prepared and used in the solid phase kinase assay with GST-cJun as substrate. As shown in Figure 7a ,b, the same concentrations of ZVAD-fmk that completely inhibited PARP-cleavage by TPA or TG (50 and 200 mM for TG and TPA, respectively: see Figure  6b ,d), did not signi®cantly in¯uence JNK activity. These results indicate that caspases that are inhibited by ZVAD-fmk are not upstream to JNK activation, which is necessary for TPA-or TG-induced apoptosis of LNCaP cells.
Discussion
The data we provide in this study show that JNK activation is required for apoptosis induced by two dierent compounds in the androgen responsive prostate cancer cell line LNCaP. There is very good correlation between the onset and time course of apoptosis induced by TPA and TG which are mechanistically expected to be dierent, and a sustained increase in JNK activity in LNCaP cells. Furthermore, speci®c inhibition of JNK activation by expression of the JNK binding domain of JIP-1 abrogates both TPA-and TG-induced apoptosis.
JNK activation in response to TPA and TG shows a biphasic activation pro®le, with an early activation at 30 min, which is reduced to basal levels by 6 h, followed by a later, sustained JNK activation that is correlated with a gradual increase in apoptosis. The magnitude of JNK activation induced by TPA at 30 min is comparable to that observed later, when apoptosis takes place. In contrast, the increase in JNK activity at 30 min by TG is modest (*twofold) compared with 5 ± 6-fold induction at 36 h when signi®cant apoptosis occurs. Rapid and transient increase in JNK activity has previously been observed with other inducers, such as tumor necrosis factor alpha (TNFa) (e.g. Sluss et al., 1994; Westwick et al., 1994) . TNFa also activated JNK in a biphasic manner in a ®broblast cell line stably expressing a fusion of murine CD4 and Fas (Roulston et al., 1998) and in primary cultures of rat brain astrocytes (Zhang et al., 1996) ; to our knowledge, these are the only other examples of biphasic JNK activation in mammalian cells described to date. At present, we do not know the role of the early and transient increase of JNK activity in response to TPA and TG treatment in LNCaP cells. It is possible that the early increase in JNK activity contributes to the later, sustained increase in JNK activity and thereby has a role in the induction of apoptosis. Alternatively, the early JNK activation could be mechanistically and causally unrelated to the later phase of JNK activation. Further work is necessary to assess the possible signi®cance of this two-tiered response and whether the early and transient JNK activation has any role in the induction of apoptosis, especially in the case of TPA.
In contrast to LNCaP cells, the androgen-independent prostate cancer cell lines PC-3 and DU-145 and (100 nM) and/or ZVAD-fmk as indicated. ZVAD-fmk (50 mM) was added 1 h prior to TG. Cells were harvested 48 h after TG addition, and whole cell extracts were made and analysed for JNK activity by the solid phase kinase assay, using GST-cJun (1 ± 93) as substrate. The experiment was repeated twice with similar results. (b) LNCaP cells were either left untreated or treated with TPA (5 ng/ml) and/or ZVAD-fmk (200 mM) as indicated. ZVAD-fmk was added 4 h prior to TPA. Cells were harvested 24 h after TPA addition, and whole cell extracts were prepared and analysed for JNK activity by the solid phase kinase assay. The experiment was repeated twice with similar results the cervical carcinoma cell line HeLa are refractory to apoptosis by TPA and show no signi®cant increase in JNK activity upon TPA treatment. However, UV irradiation potently induces JNK activity in all three cell lines, similar to that seen in LNCaP cells. These ®ndings suggest that there is not a general defect in the JNK signaling pathway in the androgen-independent cell lines PC-3 and DU-145. Instead, a component of the signaling pathway that is initiated by TPA or TG may be deregulated or regulated dierently in these cell lines compared with LNCaP cells. In line with this hypothesis, the retinoic acid analog N-(4-Hydroxyphenyl)retinamide was shown to cause both JNK-activation and apoptosis in LNCaP cells but not in PC-3 cells, while forced expression of JNK1 caused apoptosis in both cell lines (Chen et al., 1999) . It is therefore tempting to speculate that dierences in JNK signaling may contribute to the progression of prostate cancer from an androgen-dependent to an androgenindependent state. Recent ®ndings which documented an inverse correlation between expression of MKP-1, a MAPK phosphatase that preferentially inhibits the SAPKs (Franklin and Kraft, 1997; Hirsch and Stork, 1997) , and the extent of apoptosis in prostate intraepithelial hyperplasia (PIN) , the precursor of human prostate cancer, as well as in primary prostate cancer specimens (Magi-Galluzzi et al., 1997) , support our data that JNK is required for apoptosis of prostate cancer cells. In the future, it is important to extend these studies to androgen dependent prostate cancer cell lines, as they become available, as well as to in vivo model systems, such as prostate cancer xenografts.
It is not clear how an increase in JNK activity is linked to apoptosis in response to TPA and TG in LNCaP cells. JNK could stimulate the death pathway through its function as a regulator of transcription factors, like c-Jun or ATF-2, but also act by phosphorylation of other targets such as p53 or Bcl-2, which may modulate apoptosis independently of transcriptional regulation. This will be an interesting and important topic of future studies. A more general link between JNK and apoptosis, however, may be the activation of caspases. As documented here, caspases are required for both TPA-and TG-induced apoptosis in LNCaP cells, since the baculovirus caspase inhibitor P35 completely inhibits apoptosis induced by both stimuli (Figures 4 and 5) . This is consistent with recent studies which indicate the involvement of caspases in apoptosis in LNCaP cells, e.g. induced by staurosporine or PKC overexpression, since the cell permeable, general caspase inhibitor ZVAD-fmk blocked apoptosis induced by these stimuli (Zhao et al., 1997; Marcelli et al., 1999) . However, ZVAD-fmk had dierential eects on TPA-and TG-induced apoptosis in LNCaP cells (Figure 6a,c) : whereas TG-induced apoptosis was completely blocked, TPA-induced apoptosis was not aected in the presence of ZVAD-fmk. Since TPA-and TG-induced PARP cleavage was inhibited by ZVADfmk (Figure 6b,d) , caspase inhibition did occur in both cases.
What may be the basis for the dierential activities of P35 and ZVAD-fmk in LNCaP cells? P35 has been shown to inhibit all three major caspase families (Miller, 1997) . In contrast, although generally referred to as a pan-caspase inhibitor (Chow et al., 1995; Zhu et al., 1995) , ZVAD-fmk appears to have selectivity towards some caspases. For example, it has signi®-cantly lower ability to inhibit caspases 2 and 4, nearly 1000-and 50-fold weaker, respectively, compared with caspases 1 and 8 in vitro (Garcia-Calvo et al., 1998) . In addition, it cannot be ruled out that even caspase 8, which is typically activated in receptor-mediated apoptosis, is not eectively inhibited by ZVAD-fmk in vivo. Moreover, it was recently reported that ZVADfmk was threefold less ecient in blocking P53-mediated apoptosis compared with a genetic deletion of caspase-9, indicating that ZVAD-fmk may be an inecient inhibitor of caspase-9 in vivo (Soengas et al., 1999) , although it is a potent inhibitor of this caspase in vitro (Garcia-Calvo et al., 1998). Thus, it is possible that some of the above mentioned caspases, or other caspases that are yet to be discovered and that are not eciently inhibited by ZVAD-fmk, may be involved in TPA-induced apoptosis in LNCaP cells. Further work is necessary to delineate the dierential contribution of speci®c caspases to TPAand TG-induced apoptosis in LNCaP cells. Recent studies have shown that caspase-3 is not activated by TPA in LNCaP cells (Fujii et al., 2000) , while it is potently activated by TG (Wertz and Dixit, 2000) . This indicates that TPA and TG activate distinct caspase-cascades.
Since inhibition of caspases by ZVAD-fmk did not reduce JNK activity in response to TPA or TG ( Figure  7) , it is tempting to speculate that JNK mediates apoptosis in response to these signals through activation of caspases. Alternatively, caspases could be activated independently of JNK, and a concerted action of both is necessary for a full apoptotic response. Another point that should be considered is the apparent inability of ZVAD-fmk to inhibit some caspases in LNCaP cells, as indicated above; thus, at least in the case of TPA, a member of the caspase family that is not inhibited by ZVAD-fmk may be upstream to JNK. Further work is required to determine the relationship between JNK and caspases in LNCaP cells.
In summary, the data we present here suggest that JNK is involved in apoptosis of androgen sensitive prostate cancer cells. This is consistent with previous ®ndings of inverse correlation between JNK inhibitory phosphatase MKP-1 levels and apoptosis in prostate cancer tissue samples (Magi-Galluzzi et al., 1997 , and recent ®ndings which implicate the MAPKKK in apoptosis of androgen sensitive prostate cancer cells (Abreu-Martin et al., 1999) ; altogether, these results suggest that JNK activation has a role in prostate cancer. If so, JNK can be used as a target for developing treatment modalities in androgen dependent and sensitive prostate cancer, as well as in the advanced disease. (Minden et al., 1995) , GAL4-cJun , pcDNA3-Flag-JBD (a generous gift from Dr R Davis) (Dickens et al., 1997) , pCI-p35 (Bertin et al., 1997 ) (a generous gift from Dr JI Cohen) and pEGFP-C1 (Clontech) have been described previously.
Materials and methods
Plasmids
5XGAL4-LUC
Chemicals
TPA, thapsigargin, DAPI, Hoechst 33258, and trypan blue were obtained from SIGMA, and ZVAD-fmk from Alexis Biochemicals.
Cell culture
LNCaP cells (passage 6 ± 25) were obtained from ATCC and were routinely maintained in RPMI 1640 medium (Gibco-BRL), while DMEM (Gibco-BRL) was used for DU-145, PC-3 and HeLaS3 cells. All media were supplemented with 10% fetal calf serum (FCS), penicillin/streptomycin (5 mg/ ml), and L-glutamine (200 mM). Before treatment with TPA or TG, cells were kept in RPMI 1640 containing 0.5% charcoal-treated (CT) FCS for 16 ± 20 h, and maintained in the same medium throughout the treatment.
Transient transfection
For GFP cotransfection studies, LNCaP cells were transfected by lipofectin (Life Technologies) as recommended by the manufacturer. Brie¯y, 1.5610 5 cells were plated in 6-well tissue culture dishes and were transfected 2 days later, using 6.5 mg lipofectin and a total of 2 mg DNA in 1 ml of serumfree RPMI 1640. After 5 h, medium was removed and 2 ml of RPMI 1640 supplemented with 0.5% CT FCS was added. Eighteen hours later, the cells were treated with TPA (5 ng/ ml) or TG (100 nM), washed once with cold PBS, and harvested in appropriate solutions. For microscopy, cells were ®xed and processed as described below. For transfection studies using 5XGAL4-LUC, calcium phosphate method of transfecting LNCaP cells was used (Fronsdal et al., 2000) .
Apoptosis and viability assays
Cells were maintained and treated as described above. For the Trypan blue exclusion assay, cells were harvested by trypsinization and collected by centrifugation. The cell pellet was gently resuspended in a small volume of medium (100 ± 150 ml for cells from a 6 cm plate). Ten ml of cell suspension was gently mixed with 10 ml of Trypan blue (0.4%, in 0.81% NaCl and 0.06% K 3 PO 4 ). After 1 min, cells were examined under the microscope for viability indicated by Trypan blue uptake. At least three areas and a minimum of 400 cells were counted. The percentage of nonviable cells was calculated as: (#stained cells/#total cells)6100%. For detection of fragmented or condensed nuclei, cells were stained with DAPI or Hoechst 33258, and analysed bȳ uorescence microscopy.
GFP-cotransfection studies
LNCaP cells were grown in 6-well tissue culture dishes, and were transfected using lipofectin as described above. To ensure that all GFP-expressing cells should also express JBD or P35, a sevenfold excess of pcDNA3-Flag-JBD or pCI-P35 compared with pEGFP-C1 was used (0.25 mg pEGFP-C1 and 1.75 mg pcDNA3-Flag-JBD or pCI-35 per well). As a control, 0.25 mg pEGFP-C1 was cotransfected with 1.75 mg of pUC18. After transfection, the cells were maintained in RPMI 1640 containing 0.5% CT-FCS for 18 h, and TPA (5 ng/ml) or TG (100 nM) was added. TPA-treated cells were harvested after 24 h by trypsinization for 2 min, combined with the¯oating cell population, pelleted by centrifugation at 1000 r.p.m. for 3 min, washed with 1 ml PBS and resuspended in 50 ml of 2% paraformaldehyde (in PBS). After 10 min at room temperature, cells were washed once with PBS and resuspended in 20 ml PBS containing 8 mg/ml Hoechst 33258. After 15 min at room temperature in the dark, the cells were mixed with mowiol (1 : 1), mounted on glass slides, and investigated by¯uorescence microscopy. At 42 h, TG-treated cells (on coverslips) were washed with PBS at room temperature and ®xed with 0.5% glutaraldehyde (in PBS) for 5 min at room temperature. After two 5 min washes with PBS at room temperature, the cells were covered with PBS containing 1 mg/ml DAPI and 0.1% Triton X-100 at room temperature in the dark for 10 min. The cells were then washed twice with PBS and mounted on a glass slide with mowiol. Fluorescence microscopy was subsequently used to examine the nuclei of transfected (green¯uorescent) cells. Cells with condensed or fragmented nuclei were scored as apoptotic. Three areas with at least 100 transfected cells each were counted for each experimental condition, and the percentage of apoptotic cells was calculated.
Protein kinase assays
Whole cell extracts were prepared from cells that had been treated with TPA (5 ng/ml), TG (100 nM), or exposed to UV light (2 J/cm 2 for 5 s), and solid phase kinase assays were performed using GST-cJun (1 ± 93) as substrate, as described previously (Hibi et al., 1993) . After size fractionation on a 12.5% SDS ± PAGE, bands were visualized and quanti®ed using phosphorimager analysis (Molecular Dynamics).
Western analysis
Western blot analyses were performed using the ECL system (Amersham). Antisera against total JNK and phospho-JNK were from New England Biolabs, and antiserum for PARP was obtained from Boehringer Mannheim. All antisera were used according to the manufacturer's recommendations.
